查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863344

下一代腫瘤治療設備和解決方案市場（按設備類型、技術、癌症類型和最終用戶分類）—2025-2032年全球預測

Next-Generation Oncology Devices & Solutions Market by Device Type, Technology, Cancer Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，下一代腫瘤設備和解決方案市場將成長至 911.8 億美元，複合年成長率為 21.67%。

關鍵市場統計數據
基準年 2024 189.7億美元
預計年份：2025年 230.5億美元
預測年份 2032 911.8億美元
複合年成長率 (%) 21.67%

腫瘤治療設備和解決方案領域正邁入一個以技術融合、臨床精準化和以患者為中心的工作流程為特徵的新時代。分子診斷、影像學和設備自動化的進步正推動腫瘤治療從間歇性干預轉向持續的、數據驅動的管理。因此，臨床路徑正在重組，早期檢測、更精確的腫瘤表徵和自適應治療方法方案正被整合到常規實踐中。這種變革並非局限於單一技術領域，而是涵蓋診斷、影像、監測、手術和治療設備等多個學科，並將它們整合起來，從而實現封閉回路型腫瘤治療。

從概念驗證到廣泛的臨床應用，需要生產製造、監管策略、報銷途徑和機構採購等各環節的協調一致。相關人員必須應對諸多挑戰，例如日益成長的臨床證據要求、與醫療資訊科技系統的互通性以及與醫療團隊的無縫整合。因此，那些能夠將嚴謹的臨床檢驗與切實可行的商業化計劃相結合，密切關注醫護人員工作流程，並能夠向支付方和醫療系統證明其真實價值的機構，將最有可能取得成功。

人工智慧、基因組學、影像學和微創技術等新興趨勢相互融合，正在重新定義癌症治療的臨床路徑和商業模式。

臨床實務的根本轉變、技術的成熟、策略市場力量的匯聚，正加速腫瘤醫療器材生態系統的轉型。人工智慧和進階分析不再是小眾技術，而是能夠提升影像解讀效率、最佳化病理工作流程並優先考慮基因組學觀察以指導治療方案選擇的實用工具。同時，次世代定序和數位病理技術正在縮短診斷週期，並實現多模態資料整合，從而支持精準醫療。

同時，成像系統正朝著更高解析度、混合模式以及提供定量生物標記的方向發展，以改善病灶表徵和治療反應評估。穿戴式生物感測器和連續監測平台正在改變我們與患者的互動方式，並實現對治療耐受性的遠端評估。手術機器人和微創技術提高了手術的精準度，同時縮短了恢復時間。總而言之，這些變革正在改變癌症治療的提供、資金籌措和評估方式，影響臨床工作流程、資金配置和競爭格局。

關稅政策變化對癌症治療技術策略影響評估：全球供應鏈動態、設備設計、監管合規和定價

2025年美國關稅政策為腫瘤設備和解決方案領域的企業帶來了新的營運和策略考量。在製造層面，進口零件和組件成本的增加影響了費用結構，促使企業重新評估全球籌資策略。許多製造商正在考慮近岸外包、雙重採購以及建立在地採購網路，以降低關稅造成的成本波動風險。因此，供應鏈設計正從單純的成本最佳化轉向以韌性為中心的模式，強調時間安排、庫存策略和合約方面的靈活性。

除了採購之外，關稅也在加速設備架構的重新設計和材料清單(BOM) 的簡化。工程團隊正在尋求模組化設計，以減少對關稅敏感組件的依賴，並優先考慮能夠實現替代採購的標準化介面。監管和品管團隊也被迫做出調整，組件替換和供應商變更需要及時記錄和檢驗，以確保合規性。在商業方面，與醫療系統和集團採購組織的價格談判變得日益複雜，要求製造商透過透明的總擁有成本解釋和基於價值的合約方式來證明成本增加的合理性。最後，投資者和企業負責人正在重新評估資本支出計畫和併購活動，以精簡供應鏈、保護智慧財產權，並在能夠降低關稅風險的地區加強製造地。

按設備、技術、癌症類型和最終用戶進行細分，揭示了腫瘤治療領域不同的發展重點和應用趨勢。

了解腫瘤醫療器材細分市場的細微差別對於指導產品開發重點和商業化路徑至關重要。醫療器材分類包括：診斷系統，例如免疫組織化學和螢光雜合反應；分子平台，例如聚合酵素鏈鎖反應(PCR)，包括數位 PCR 和定量 PCR；以及次世代定序(NGS)，涵蓋EXOME定序、標靶基因組定序和全基因測序方法。影像技術涵蓋了從錐狀射束和多切面螺旋電腦斷層掃描 (CT) 平台到 1.5T 和 3T 磁場強度的磁振造影(MRI) 系統，以及正子斷層掃描 (PET) 解決方案，包括 PET/CT 和 PET/MRI 混合設備。超音波設備涵蓋了從傳統2D成像到先進的3D和四維成像功能，X光系統則包括電腦放射成像 (CR)數位放射線放射成像 (DR)。監測解決方案擴大整合生物感測器和穿戴式設備，以實現長期數據收集。我們的外科手術器械包括冷凍手術器械、腹腔鏡技術和支援精準介入手術的機器人平台。我們的治療設備產品組合涵蓋藥物傳輸系統和放射治療設備，而我們的放射治療解決方案則包括近距離近距離放射系統、直線加速器和質子治療機。

技術主導的細分進一步明確了採用路徑和投資重點。人工智慧正透過數據分析、深度學習和機器學習得到應用，旨在提高診斷準確性和營運效率。生物資訊能力圍繞著次世代定序資料分析和蛋白質體學流程展開，而數位病理學投資則專注於影像分析軟體和全切片成像平台。奈米技術的發展包括用於靶向遞送的奈米載體和用於提高靈敏度的奈米診斷技術。機器人技術繼續區分專用活體組織切片系統和針對切片檢查工作流程最佳化的手術機器人。按癌症類型（例如乳癌、結直腸癌、肺癌和前列腺癌）分類的臨床重點影響著診斷和治療的優先順序，而最終用戶細分（包括門診中心、診斷實驗室、醫院和研究機構）則決定了採購週期、IT整合需求和實施所需的證據。整合這些細分層級使產品團隊和商業領導者能夠針對不同的臨床和組織購買者需求，並制定相應的功能集、臨床檢驗計劃和服務模式。

區域比較分析突顯了法規結構、臨床基礎設施和製造地對腫瘤醫療器材應用和市場發展路徑的影響

區域趨勢對癌症醫療器材和解決方案的監管要求、上市時間表和商業化路徑有顯著影響。在美洲，完善的臨床試驗基礎設施、眾多專業癌症中心以及重視臨床和經濟價值證據的支付方環境，正在加速創新診斷方法和醫療器材的普及應用。該地區也是醫療器材製造和風險投資的熱點地區，這既有利於快速的商業化週期，也要求嚴格的上市後監測和真實世界證據的累積。

歐洲、中東和非洲地區呈現多元化的格局，監管協調工作與各國特有的報銷流程和採購行為並存。在一些市場，集中核准和基於價值的採購機制促進了跨境應用，而其他地區（中東除外）的資源限制則要求採用成本效益高且可擴展的解決方案。該地區複雜的報銷結構和多樣化的臨床實踐模式凸顯了模組化產品模式和靈活商業策略的重要性。亞太地區擁有龐大的市場規模，同時技術應用迅速，本地製造能力不斷提升，並且公共對精準醫療進行了戰略性投資。亞太主要市場的監管機構正日益接受對具有高臨床效用的醫療設備的加速核准途徑，使區域製造商能夠成為全球供應鏈中具有競爭力的供應商。在所有地區，醫療器材的應用都受到當地勞動力能力、數位基礎設施成熟度以及支持早期檢測、患者就醫和癌症監測的國家政策重點的影響。

現有平台公司、專業創新者和策略聯盟正透過整合解決方案、智慧財產權策略和服務主導的差異化重新定義競爭格局。

腫瘤醫療設備和解決方案領域的競爭格局呈現出多元化的特點，既有大型平台供應商，也有專注於技術的專業公司，還有致力於提供以臨床為導向的創新產品的敏捷型Start-Ups。成熟的醫療技術公司利用其廣泛的商業管道、服務網路和監管經驗，擴展其整合的硬體、軟體和服務解決方案。同時，一些專注於特定領域的公司往往在分子診斷、數位病理學和機器人等領域推進顛覆性技術，迫使現有企業透過合作、授權或進行有針對性的收購來維持其臨床競爭力。

在尋求建構端到端價值提案的企業中，醫療設備製造商、軟體公司和臨床研究機構之間的策略聯盟正變得越來越普遍。以演算法、設備介面和組件設計為核心的智慧財產權組合是關鍵的差異化因素，而生產規模和供應商關係則構成了成本競爭力的基礎。此外，越來越多的公司正在拓展產品範圍，涵蓋資訊服務、臨床決策支援和生命週期管理，從而創造持續的收入來源並加深客戶參與。對於銷售團隊而言，了解競爭對手在證據產生、報銷支援和售後服務方面的定位，對於建構制勝的價值提案至關重要。

經營團隊需應對一系列切實可行的策略挑戰，包括加強供應鏈、收集證據、實現產品模組化以及建構商業模式，以確保永續的競爭優勢。

產業領導者必須採取多管齊下的策略，抓住下一代腫瘤治療設備帶來的機遇，同時降低系統性風險。首先，供應鏈韌性應成為策略重點。供應商多元化、盡可能投資近岸製造以及重新設計產品以提高組件彈性，都能降低政策驅動型干擾所帶來的風險。同時，企業應優先產生符合支付方要求和機構採購標準的可靠臨床和衛生經濟學證據。儘早與臨床醫生、衛生技術評估機構和支付方決策者合作，可以確保研究設計和資料收集能夠涵蓋最相關的終點指標。

產品策略應強調互通性、模組化和軟體驅動的升級路徑，以支援延長產品生命週期和逐步推出新功能。銷售部門應制定符合醫療服務提供者獎勵的定價和合約模式（包括在適當情況下採用按績效付費合約），並加強銷售能力，以支持醫院和研究機構複雜的銷售週期。對上市後資料收集和真實世界證據平台的投資，不僅可以增強監管和報銷審查資料，還能為迭代式產品改進提供可操作的見解。最後，組織優先事項應包括人才策略，以吸引臨床、監管和數位化領域的專業人才，並建立一種強調快速、循證迭代的企業文化，以跟上臨床創新的步伐。

調查方法結合了專家訪談、監管和臨床證據審查以及多方面的檢驗，以確保獲得可靠且實用的見解。

本分析所依據的研究採用多層調查方法，以確保研究的嚴謹性、多方驗證以及與相關人員的相關性。主要研究包括對醫療設備製造商和醫院系統的臨床意見領袖、採購負責人、監管專家和高階主管進行結構化訪談。這些定性研究結果輔以對公開的監管文件、臨床試驗註冊資訊、同行資訊披露文獻和專利揭露的系統性審查，以識別技術趨勢和證據缺口。此外，還透過分析公司新聞稿、產品公告和投資者報告，進一步檢驗了市場和技術趨勢，以了解其策略意圖和資源分配。

定量分析輔以資料集綜合和交叉檢驗程序，以確保資訊來源的一致性。必要時，進行敏感度分析和情境測試，以探討不同法規環境和政策環境下的影響。整個過程實施了品管，包括資訊來源重的調查方法標準、領域專家的同儕審查以及保護訪談隱私的倫理保障措施。研究承認並克服了其局限性，透過收集不同地區、技術成熟度水準和製度背景下的多元觀點，確保結論穩健可靠，並能為決策者提供切實可行的指導。

摘要重點介紹了整合的臨床平台、實證商業化以及應對政策和區域差異的能力。

摘要，下一代腫瘤設備和解決方案將由整合高精度診斷、先進影像、智慧軟體和微創治療的平台構成，從而建立臨床路徑。能夠將卓越技術與臨床證據、監管前瞻性和靈活的商業模式相結合的機構將獲得成功。關稅政策的波動、區域監管差異以及不斷變化的支付方預期等外部因素將繼續影響策略選擇，進一步提升對適應性供應鏈和基於價值的定價方法的需求。

積極主動地將產品策略與臨床工作流程相結合、投資生成真實世界數據 (RWE) 並促進整個生態系統夥伴關係的相關人員，將更有利於加速精準腫瘤學的普及應用並充分發揮其潛力。相反，那些研發結構缺乏跨職能協調、對上市後數據投入不足或未能預見政策主導的成本壓力的公司，則可能面臨普及速度放緩和利潤率下降的風險。未來的道路需要嚴謹的執行、跨職能的協作，以及始終專注於向病患、醫療服務提供者和支付者展現切實的臨床和經濟價值。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧成像技術與即時腫瘤邊緣檢測相結合應用於外科腫瘤學
  • 開發用於早期癌症檢測和監測的多重液態生物檢體檢測方法
  • 利用穿戴式生物感測器連續監測化療引起的心臟毒性
  • 基於奈米顆粒的固態腫瘤靶向藥物遞送系統的研究進展
  • 推出雲端基礎的平台，用於安全地共用癌症患者的基因組數據
  • 黑色素瘤患者個人化免疫療法選擇的伴隨診斷技術的發展
  • 低場可攜式磁振造影系統在偏遠診所照護現場腫瘤表徵的應用

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 下一代腫瘤設備和解決方案市場（按設備類型分類）

  • 診斷設備
    • 螢光原位雜合反應
    • 免疫組織化學
    • 次世代定序
      • EXOME定序
      • 目標面板
      • 全基因測序
    • 聚合酵素鏈鎖反應
      • 數位PCR
      • 定量PCR
  • 診斷影像設備
    • 電腦斷層掃描
      • 錐狀射束CT
      • 多切面CT
    • 磁振造影
      • 1.5T成像
      • 3T成像
    • 正子斷層掃描
      • PET/CT混合
      • PET/MRI混合
    • 超音波影像
      • 2D成像
      • 3D/4D成像
    • X光影像診斷
      • 電腦放射成像
      • 數位放射線
  • 監控設備
    • 生物感測器
    • 穿戴式裝置
  • 手術器械
    • 冷凍手術
    • 腹腔鏡手術
    • 機器人手術
  • 治療設備
    • 藥物輸送裝置
    • 放射治療設備
      • 近距離放射系統
      • 直線加速器
      • 質子治療系統

9. 按技術分類的下一代腫瘤設備和解決方案市場

  • 人工智慧
    • 數據分析
    • 深度學習
    • 機器學習
  • 生物資訊學
    • 次世代定序（NGS）資料分析
    • 蛋白質體學數據分析
  • 數位病理學
    • 影像分析軟體
    • 全切片成像
  • 奈米科技
    • 奈米載體
    • 奈米診斷
  • 機器人技術
    • 切片檢查機器人
    • 手術機器人

第10章：按癌症類型分類的下一代腫瘤設備和解決方案市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 攝護腺癌

第11章：按最終用戶分類的下一代腫瘤設備和解決方案市場

  • 門診治療中心
  • 診斷實驗室
  • 醫院
  • 研究所

12. 下一代腫瘤設備和解決方案市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：按組別分類的下一代腫瘤設備和解決方案市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國下一代腫瘤設備與解決方案市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Siemens Healthineers AG
    • General Electric Company
    • Koninklijke Philips NV
    • Accuray Incorporated
    • Ion Beam Applications SA
    • Brainlab AG
    • ViewRay, Inc.
    • Mevion Medical Systems, Inc.
    • RaySearch Laboratories AB
Product Code: MRR-2E76C3E47F6D

The Next-Generation Oncology Devices & Solutions Market is projected to grow by USD 91.18 billion at a CAGR of 21.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.97 billion
Estimated Year [2025] USD 23.05 billion
Forecast Year [2032] USD 91.18 billion
CAGR (%) 21.67%

The oncology devices and solutions landscape is entering an era defined by technological convergence, clinical precision, and a relentless drive toward patient-centered workflows. Advances in molecular diagnostics, imaging modalities, and device automation are moving oncology care from episodic intervention toward continuous, data-driven management. As a result, clinical pathways are being reconfigured to embed earlier detection, more accurate tumor characterization, and adaptive therapeutic delivery in routine practice. This evolution is not limited to a single technology class; instead, it spans diagnostic, imaging, monitoring, surgical, and therapeutic devices that together enable closed-loop oncologic care.

Transitioning from proof of concept to widespread clinical adoption requires alignment across manufacturing, regulatory strategy, reimbursement pathways, and institutional procurement. Stakeholders must navigate heightened expectations for clinical evidence, interoperability with health IT systems, and seamless integration into care teams. Consequently, the most successful organizations will be those that combine rigorous clinical validation with pragmatic commercialization plans, an acute sensitivity to provider workflows, and an ability to demonstrate real-world value to payers and health systems.

How emerging AI, genomics, imaging, and minimally invasive technologies are converging to redefine clinical pathways and commercial models in oncology care

Fundamental shifts in clinical practice, technology maturation, and strategic market behavior are collectively accelerating transformation across the oncology device ecosystem. Artificial intelligence and advanced analytics are no longer niche capabilities; they are operational tools that enhance image interpretation, streamline pathology workflows, and prioritize genomic findings for treatment selection. Concurrently, next-generation sequencing and digital pathology are reducing diagnostic turnaround times and enabling multi-modal data synthesis that supports precision medicine.

In parallel, imaging systems have evolved to offer higher resolution, hybrid modalities, and quantitative biomarkers that improve lesion characterization and response assessment. Wearable biosensors and continuous monitoring platforms are transforming patient engagement and enabling remote assessment of therapy tolerability. Surgical robotics and minimally invasive techniques are refining procedural accuracy while reducing recovery time. Taken together, these shifts are changing how oncology care is delivered, financed, and measured, with implications for clinical workflows, capital allocation, and the competitive landscape.

Assessing the strategic consequences of tariff policy shifts on global supply chains, device design, regulatory compliance, and pricing dynamics across oncology technologies

The implementation of United States tariffs in 2025 has introduced a new set of operational and strategic considerations for companies involved in oncology devices and solutions. At the manufacturing level, cost structures have been affected by increased expenses for imported components and subassemblies, which in turn has encouraged a reassessment of global sourcing strategies. Many manufacturers are evaluating nearshoring, dual-sourcing, and localized supplier networks to mitigate exposure to tariff-driven cost volatility. As a consequence, supply chain design has shifted from a pure cost-optimization focus to a resilience-centric model that emphasizes timing, inventory strategies, and contractual flexibility.

Beyond procurement, tariffs have accelerated redesign efforts for device architecture and bill-of-material simplification. Engineering teams are seeking modular designs that reduce reliance on tariff-sensitive components and prioritize standardized interfaces to enable alternative sourcing. Regulatory affairs and quality teams are also adapting, as component substitutions and supplier changes require timely documentation and revalidation to maintain compliance. On the commercial front, pricing negotiations with health systems and group purchasing organizations have become more complex, with manufacturers needing to substantiate cost increases through transparent total cost of ownership narratives and value-based contracting approaches. Finally, investors and corporate strategists are reassessing capex plans and M&A activity to capture supply chain efficiencies, secure intellectual property, and shore up manufacturing footprints in jurisdictions that reduce tariff exposure.

Unpacking device, technology, cancer type, and end user segmentation to reveal differentiated development priorities and adoption dynamics across oncology care

A nuanced understanding of segmentation is essential to navigate product development priorities and commercialization pathways across oncology devices. Device classifications span diagnostic systems such as immunohistochemistry and fluorescence in situ hybridization, molecular platforms including polymerase chain reaction with digital and quantitative PCR formats, and next-generation sequencing which itself encompasses exome sequencing, targeted panels, and whole genome sequencing approaches. Imaging technologies range from computed tomography platforms with cone beam and multi-slice configurations to magnetic resonance imaging systems offered in 1.5T and 3T field strengths, alongside positron emission tomography solutions available as PET/CT and PET/MRI hybrids. Ultrasound offerings vary from conventional two-dimensional imaging to advanced three-dimensional and four-dimensional capabilities, while X-ray systems exist in computed radiography and digital radiography forms. Monitoring solutions increasingly incorporate biosensors and wearable devices to enable longitudinal data capture, whereas surgical tools include cryosurgery, laparoscopic techniques, and robotic platforms that support precision interventions. Therapeutic device portfolios cover drug delivery systems and radiation therapy modalities, with radiation solutions spanning brachytherapy systems, linear accelerators, and proton therapy installations.

Technology-driven segmentation further clarifies adoption pathways and investment focus. Artificial intelligence is being applied through data analytics, deep learning, and machine learning to enhance diagnostic yield and operational efficiency. Bioinformatics capabilities are centered on next-generation sequencing data analysis and proteomics pipelines, while digital pathology investments emphasize image analysis software and whole slide imaging platforms. Nanotechnology development includes nanocarriers for targeted delivery and nanodiagnostics to improve sensitivity, and robotics continues to differentiate into biopsy-specific systems and surgical robotics optimized for oncology workflows. Clinical focus across cancer types-such as breast, colorectal, lung, and prostate cancers-affects diagnostic and therapeutic priorities, and end-user segmentation encompassing ambulatory care centers, diagnostic laboratories, hospitals, and research institutes determines procurement cycles, IT integration needs, and evidence requirements for adoption. Synthesizing these layers of segmentation enables product teams and commercial leaders to target feature sets, clinical validation plans, and service models that align with distinct clinical and institutional buyer needs.

Comparative regional analysis revealing how regulatory frameworks, clinical infrastructure, and manufacturing footprints influence oncology device adoption and market pathways

Regional dynamics exert a powerful influence on regulatory expectations, adoption timelines, and commercialization pathways across oncology devices and solutions. In the Americas, strong clinical trial infrastructure, a concentration of specialized cancer centers, and payer environments that increasingly reward evidence of clinical and economic value combine to accelerate uptake of innovative diagnostics and devices. This region also remains a focal point for device manufacturing and venture investment, which supports rapid commercialization cycles while demanding robust post-market surveillance and real-world evidence generation.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization initiatives coexist with country-specific reimbursement processes and procurement behaviors. In some markets, centralized approvals and value-based procurement mechanisms encourage cross-border adoption, whereas resource constraints in other jurisdictions necessitate cost-effective, scalable solutions. The region's complex reimbursement tapestry and diverse clinical practice patterns place a premium on modular product models and flexible commercial strategies. Asia-Pacific exhibits a blend of high-volume markets with fast technology adoption, alongside growing local manufacturing capability and strategic public investments in precision medicine. Regulatory authorities in key Asia-Pacific markets are increasingly receptive to expedited pathways for devices demonstrating strong clinical utility, and regional manufacturers are becoming competitive suppliers for global supply chains. Across all regions, adoption is shaped by local workforce capacity, digital infrastructure maturity, and national policy priorities that support early detection, patient access, and cancer research.

How incumbent platforms, focused innovators, and strategic collaborations are redefining competition through integrated solutions, IP positioning, and service-driven differentiation

The competitive landscape in oncology devices and solutions is defined by a mix of large platform providers, specialized technology companies, and agile startups that bring focused innovations to clinical practice. Established medical technology firms leverage broad commercial channels, service networks, and regulatory experience to scale integrated solutions that combine hardware, software, and servicing. Meanwhile, niche companies often advance disruptive capabilities in areas such as molecular diagnostics, digital pathology, and robotics, forcing incumbents to pursue partnerships, licensing agreements, or targeted acquisitions to retain clinical relevance.

Strategic collaborations between device manufacturers, software companies, and clinical research organizations are increasingly common as firms seek to assemble end-to-end value propositions. Intellectual property portfolios centering on algorithms, device interfaces, and component designs serve as key differentiators, while manufacturing scale and supplier relationships underpin cost competitiveness. Moreover, a growing number of companies are expanding offerings beyond product delivery to include data services, clinical decision support, and lifecycle management, thereby creating recurring revenue streams and deeper customer engagement. For commercial teams, understanding competitor positioning across evidence generation, reimbursement support, and aftermarket services is critical to crafting winning value propositions.

Actionable strategic imperatives for executives to strengthen supply chains, evidence generation, product modularity, and commercial models to secure lasting competitive advantage

Industry leaders must adopt a multi-dimensional approach to capture the opportunities presented by next-generation oncology devices while mitigating systemic risks. First, supply chain resilience should be elevated to strategic priority status; diversifying suppliers, investing in near-shore manufacturing where feasible, and redesigning products for component flexibility will reduce exposure to policy-driven disruptions. Simultaneously, companies should prioritize the generation of robust clinical and health economic evidence that aligns with payer requirements and institutional procurement criteria. Early engagement with clinicians, health technology assessment bodies, and payer decision-makers ensures that trial designs and data collection address the most relevant endpoints.

Product strategy should emphasize interoperability, modularity, and software-enabled upgrade paths to extend product lifecycles and support incremental feature deployment. Commercial teams need to craft pricing and contracting models that align provider incentives, including outcomes-based agreements where appropriate, and to build commercial capabilities that support complex sales cycles within hospitals and research institutes. Investing in post-market data capture and real-world evidence platforms not only strengthens regulatory and reimbursement dossiers but also supplies actionable insights for iterative product improvement. Finally, organizational priorities should include talent strategies that attract clinical, regulatory, and digital expertise, and a culture that values rapid evidence-driven iteration to keep pace with clinical innovation.

Methodological framework combining expert interviews, regulatory and clinical evidence review, and multi-source triangulation to ensure robust and actionable insights

The research underpinning this analysis relied on a layered methodology intended to ensure rigor, triangulation, and relevance to stakeholders. Primary research included structured interviews with clinical opinion leaders, procurement professionals, regulatory experts, and senior executives across device manufacturers and hospital systems. These qualitative inputs were complemented by a systematic review of publicly available regulatory filings, clinical trial registries, peer-reviewed literature, and patent disclosures to identify technology trajectories and evidence gaps. Market and technology signals were further validated through analysis of company press releases, product launch materials, and investor presentations to capture strategic intent and resource allocation.

Quantitative analysis was supported by dataset integration and cross-validation routines to ensure consistency across sources. Where appropriate, sensitivity analyses and scenario testing were used to explore implications under different regulatory or policy environments. Throughout the process, quality controls included methodological rubrics for source weighting, peer review by domain experts, and ethical safeguards to protect interview confidentiality. Limitations of the research were acknowledged and addressed by seeking diverse viewpoints across geographies, technology maturity levels, and institutional contexts, ensuring that conclusions are robust and actionable for decision-makers.

Concluding synthesis emphasizing integrated clinical platforms, evidence-driven commercialization, and resilience in the face of policy and regional variability

In summary, the next wave of oncology devices and solutions will be defined by platforms that integrate high-fidelity diagnostics, advanced imaging, intelligent software, and minimally invasive therapeutics into coherent clinical pathways. Success will favor organizations that can harmonize engineering excellence with clinical evidence, regulatory foresight, and flexible commercial models. External forces such as tariff policy shifts, regional regulatory variability, and evolving payer expectations will continue to shape strategic choices, reinforcing the need for adaptable supply chains and value-based pricing approaches.

Stakeholders that proactively align product strategies with clinical workflows, invest in real-world evidence generation, and cultivate partnerships across the ecosystem will be best positioned to accelerate adoption and realize the promise of precision oncology. Conversely, firms that maintain siloed development, under-invest in post-market data, or fail to anticipate policy-driven cost pressures risk slower uptake and margin compression. The path forward requires disciplined execution, cross-functional coordination, and a relentless focus on demonstrating tangible clinical and economic value to patients, providers, and payers alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-powered imaging with real-time tumor margin detection in surgical oncology
  • 5.2. Development of multiplexed liquid biopsy assays for early-stage cancer detection and monitoring
  • 5.3. Adoption of wearable biosensors for continuous monitoring of chemotherapy-induced cardiotoxicity
  • 5.4. Advancements in nanoparticle-based targeted drug delivery systems for solid tumors
  • 5.5. Implementation of cloud-based platforms for secure sharing of oncology patient genomic data
  • 5.6. Growth of companion diagnostics for personalized immunotherapy selection in melanoma patients
  • 5.7. Emergence of low-field portable MRI systems for point-of-care tumor characterization in remote clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Oncology Devices & Solutions Market, by Device Type

  • 8.1. Diagnostic Devices
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Immunohistochemistry
    • 8.1.3. Next Generation Sequencing
      • 8.1.3.1. Exome Sequencing
      • 8.1.3.2. Targeted Panels
      • 8.1.3.3. Whole Genome Sequencing
    • 8.1.4. Polymerase Chain Reaction
      • 8.1.4.1. Digital PCR
      • 8.1.4.2. Quantitative PCR
  • 8.2. Imaging Devices
    • 8.2.1. Computed Tomography
      • 8.2.1.1. Cone Beam CT
      • 8.2.1.2. Multi-Slice CT
    • 8.2.2. Magnetic Resonance Imaging
      • 8.2.2.1. 1.5T Imaging
      • 8.2.2.2. 3T Imaging
    • 8.2.3. Positron Emission Tomography
      • 8.2.3.1. PET/CT Hybrid
      • 8.2.3.2. PET/MRI Hybrid
    • 8.2.4. Ultrasound Imaging
      • 8.2.4.1. 2D Imaging
      • 8.2.4.2. 3D/4D Imaging
    • 8.2.5. X-Ray Imaging
      • 8.2.5.1. Computed Radiography
      • 8.2.5.2. Digital Radiography
  • 8.3. Monitoring Devices
    • 8.3.1. Biosensors
    • 8.3.2. Wearable Devices
  • 8.4. Surgical Devices
    • 8.4.1. Cryosurgery
    • 8.4.2. Laparoscopic Surgery
    • 8.4.3. Robotic Surgery
  • 8.5. Therapeutic Devices
    • 8.5.1. Drug Delivery Devices
    • 8.5.2. Radiation Therapy Devices
      • 8.5.2.1. Brachytherapy Systems
      • 8.5.2.2. Linear Accelerators
      • 8.5.2.3. Proton Therapy Systems

9. Next-Generation Oncology Devices & Solutions Market, by Technology

  • 9.1. Artificial Intelligence
    • 9.1.1. Data Analytics
    • 9.1.2. Deep Learning
    • 9.1.3. Machine Learning
  • 9.2. Bioinformatics
    • 9.2.1. NGS Data Analysis
    • 9.2.2. Proteomics Data Analysis
  • 9.3. Digital Pathology
    • 9.3.1. Image Analysis Software
    • 9.3.2. Whole Slide Imaging
  • 9.4. Nanotechnology
    • 9.4.1. Nanocarriers
    • 9.4.2. Nanodiagnostics
  • 9.5. Robotics
    • 9.5.1. Biopsy Robotics
    • 9.5.2. Surgical Robotics

10. Next-Generation Oncology Devices & Solutions Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. Next-Generation Oncology Devices & Solutions Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Next-Generation Oncology Devices & Solutions Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Next-Generation Oncology Devices & Solutions Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Next-Generation Oncology Devices & Solutions Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Siemens Healthineers AG
    • 15.3.2. General Electric Company
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Accuray Incorporated
    • 15.3.5. Ion Beam Applications S.A.
    • 15.3.6. Brainlab AG
    • 15.3.7. ViewRay, Inc.
    • 15.3.8. Mevion Medical Systems, Inc.
    • 15.3.9. RaySearch Laboratories AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOL